Answers are grounded in this paper and cite their sources.
A female in her late teens, a habitual contact lens wearer, presented with a 15-day history of reduced vision, watering, and photophobia in her left eye. She had been treated elsewhere with topical antibiotics and lubricants without improvement. Examination revealed an 8 × 7 mm subtotal corneal epithelial defect with few stromal infiltrates [Figure 1a]. Prior culture had confirmed Pseudomonas aeruginosa keratitis.Figure 1: Slit-lamp photographs showing the effect of topical insulin therapy on a persistent epithelial defect in a contact lens wearer following Pseudomonas keratitis. (Top row: diffuse, bottom row: cobalt blue), (a) at presentation: subtotal epithelial defect with fluorescein staining, (b) after 1 week of topical insulin: partial healing with ~25% size reduction, (c) after 2 weeks: complete re-epithelialisation with residual leucomatous opacityDespite intensive inpatient fortified antibiotics and lubricants, the epithelial defect persisted. Off-label topical insulin (1 IU/mL, prepared by diluting regular human insulin in artificial tears) was initiated four times daily. Within one week, the defect had reduced by 25% [Figure 1b]. Complete and stable re-epithelialisation was achieved by two weeks [Figure 1c], leaving a dense leucomatous scar. No local or systemic side effects were observed. Persistent epithelial defects complicating microbial keratitis represent a major therapeutic challenge, particularly in contact lens wearers, where Pseudomonas is an aggressive pathogen. The loss of corneal nerves and damage to limbal stem cells disrupt epithelial healing mechanisms, predisposing to corneal thinning and scarring.[1] Conventional adjunctive therapies—autologous serum eye drops, amniotic membrane transplantation, or recombinant nerve growth factor—are often inaccessible due to cost, logistical demands, or limited availability in resource-constrained settings.[1–3] Topical insulin offers a safe, inexpensive, and widely available alternative. By acting on corneal insulin/IGF-1 receptors and activating the PI3K/Akt and RAS/ERK pathways, it promotes epithelial proliferation and migration.[4] Clinical series report closure of up to 80% of refractory persistent epithelial defects with median healing times shorter than with autologous serum.[2–4] This case highlights the role of topical insulin as a readily accessible adjunct in managing persistent epithelial defects secondary to bacterial keratitis in contact lens users, with the potential to prevent escalation to surgical interventions.[1,4,5] Patient consent Written informed consent for publication of clinical details and images was obtained.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: